ISPO

READ BY TITLE Clinical application of sCD44v6 in diagnosis of colorectum carcinoma and monitoring response to therapy

Jiannong Zhou

Cancer Hospital and Institute of Jiangsu Province, Nanjing 210009, China

AIM Colorectum carcinoma is one of the most common tumors. This work explores the role of sCD44v6 in the diagnosis of colorectum carcinoma and monitoring its metastasis and prognosis. METHODS The concentrations of sCD44v6 in sera of 24 healthy persons as control and 96 colorectum carcinoma patients in three different Dukes' stages (II, III and IV) before surgery were detected by using ELISA. The CEA levels in these serum specimen were detected by using ELISA for comparison. RESULTS The level of serum sCD44v6 in the patient group was 275.3±115.8 ng/ml, which was much higher than 61.3 ±7.8 ng/ml of healthy controls. The levels of serum sCD44v6 between the different groups of colorectum carcinoma patients or Duke's’ stages were of significant difference (P<0.05) and increased with increasing Dukes’ stage. The CEA level in the patient group was also higher than that of healthy control and showed a significant difference between two group (P<0.05), however, no significant difference (P>0.05) is observed between the different stages of colorectum carcinoma. CONCLUSIONS The level of sCD44v6 is closely related to the focus of colorectum carcinoma and its metastasis, while CEA level can not be used to monitor the treatment efficiency and the prognosis of colorectum carcinoma. Thus sCD44v6 is a more valuable marker and can be used for the diagnosis of colorectum carcinoma and monitoring and expressing its prognosis and metastasis. The method based on the determination of sCD44v6 level provides a high sensitive technique for the diagnosis of the tumor metastasis.

For more information, contact hxju@jlonline.com

Paper presented at the International Symposium on Predictive Oncology and Intervention Strategies; Paris, France; February 9 - 12, 2002; in the section on Diagnostic Markers.

http://www.cancerprev.org/Journal/Issues/26/101/1291/4531